Desmopressin intranasal - CPX Pharmaceuticals/Serenity Pharmaceuticals

Drug Profile

Desmopressin intranasal - CPX Pharmaceuticals/Serenity Pharmaceuticals

Alternative Names: Desmopressin acetate; Intranasal desmopressin - Serenity Pharmaceuticals; Noctiva; SER 120

Latest Information Update: 21 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CPEX Pharmaceuticals; Serenity Pharmaceuticals Corporation
  • Developer Serenity Pharmaceuticals Corporation
  • Class Antidiuretics; Antihaemorrhagics; Hormones; Urologics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Nocturia

Most Recent Events

  • 17 Aug 2017 Serenity Pharmaceuticals enters into a negotiation with Avadel Pharmaceuticals for development and commercialisation of desmopressin intranasal in USA and Canada
  • 03 Mar 2017 Registered for Nocturia (In the elderly) in USA (Intranasal)
  • 03 Mar 2017 Registered for Nocturia in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top